While President Lee Jae Myung mentioned the need for a drug that induces pregnancy suspension, the government has begun legalizing the drug "Mifgin" for pregnancy suspension and considering establishing a public management system. The intention is to incorporate abortion drugs into the system, which have relied on illegal distribution, in the legislative vacuum that has continued for seven years since the decision to be inconsistent with the constitution for abortion.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Shim Hee-jin
Seoul Asan, Samsung Medical Center dominate AP hospital rankings
South Korea’s healthcare sector earned global recognition once again as Asan Medical Center and Samsung Medical Center claimed the top spot in eight of 10 clinical specialties in the latest Asia-Pacific hospital rankings. Newsweek and global market research firm Statista released their 2026 Best Hospitals Asia-Pacific rankings on Thursday.
No. of Koreans traveling to Japan for stem cell treatments soar
The number of South Koreans traveling to Japan for immune cell therapy, which is banned in Korea, has been surging. Although the treatment costs at least several million won, patients feel they have no choice due to the lack of options in Korea. While countries such as Japan, the United States, and Europe actively foster regenerative medicine industries using stem cells, Korea remains hindered by regulatory restrictions.
Cerecin on track to develop oral dementia drug
Cerecin Inc., a global biotechnology company focused on neurology drug development, is developing a new drug candidate for Alzheimer’s disease in liquid form. This is easier to ingest than injections, which take over an hour to administer, or pills that need to be swallowed, according to Chief Executive Officer Charles Stacey. “Since dementia is a degenerative disease, the majority of patients are elderly.
Samsung Biologics, Bioepis partner with Yonsei University to nurture talent
Samsung Biologics Co. and Samsung Bioepis Co. have teamed up with Yonsei University to foster talent in the field of bio research and development (R&D). The two companies signed a memorandum of understanding (MOU) with the university on Wednesday on establishing a Bio Talent Development Track within the university’s College of Life Systems.
Yunovia accelerates development of obesity, diabetes treatments
Yunovia Co., a biotech subsidiary of Ildong Pharmaceutical Co., is expected to move on to the next phase of clinical trials to verify the safety of its new drug candidate aimed at treating diabetes and obesity. Ildong Pharmaceutical said on Monday that Yunovia is moving forward with a multiple ascending dose (MAD) study, which is the follow-up phase to the Phase 1 clinical trial for its drug candidate, ID110521156.
MedySapiens’ solution recognized as innovative product
The South Korean government recognized biotechnology company MedySapiens’ rare genetic disease solution as an innovative product. MedySapiens announced on Monday that its genome variant analysis solution for rare genetic diseases, MedySOL, was designated as an innovative product by the Ministry of Trade, Industry and Energy. The government designates breakthrough products as innovative products and provides support and benefits to ensure further market opportunities.
NGeneBio to supply tumor RNA diagnosis products to Asan Medical Center
NGeneBio, a major next-generation sequencing (NGS) diagnostic platform company, announced on Thursday that it will supply its advanced RNA precision diagnostic product, ONCOaccuPanel RNA, to Asan Medical Center in Seoul. ONCOaccuPanel RNA was developed by NGeneBio based on technology transferred from the hospital.
Samsung Biologics nabs landmark $1bn-plus CMO deal
Samsung Biologics won a big deal exceeding $1 billion for contract manufacturing, a significant milestone in the company’s history. The deal accounts for approximately 40 percent of 2023’s total order value. Its subsidiary, Samsung Bioepis, is concurrently expediting its entry into the U.S. market with FDA approval for a new biosimilar. Samsung Biologics announced the signing of a record-breaking CMO deal worth 1.46 trillion won ($1.05 billion) with a U.S.-based pharmaceutical company on Tuesday.
SK bioscience acquires IDT Biologika for new growth opportunity
SK bioscience has acquired a 60 percent stake in Germany’s IDT Biologika for 339 billion won ($245 million). This deal is a strategic move aligned with the company’s asset rebalancing efforts, according to SK bioscience CEO Ahn Jae-yong. SK bioscience CEO Ahn Jae-yong held a press conference in Seoul on Thursday to discuss the acquisition and the company’s future plans.
IMBiologics inks $964 mn license deal with U.S. firm
South Korean antibody drug startup IMBiologics announced on Monday that it signed a license deal for two autoimmune disease treatment candidates with Navigator Medicines in the United States. The contract is valued at about 1.3 trillion won ($964 million), inclusive of upfront payments and milestone-based fees.
Roche in talks with Korean biotech companies for collaboration
Roche Holding AG, a multinational healthcare company based in Switzerland, is in discussion with about 200 South Korean biotech companies for partnerships, according to Harm-Jan Borgeld, head of Asia partnering at Roche.
Merck KGaA to invest $323mn to build bio facility in Daejeon
Germany’s Merck KGaA, a leading global company in science and technology, will invest about 430 billion won ($323 million) to build a bio raw material production facility in Daejeon, South Korea. According to the company on Thursday, it will establish the facility in Dungok District in Daejeon.
Merck KGaA to invest $323mn to build bio facility in Daejeon
Germany's Merck KGaA, a leading global company in science and technology, will invest about 430 billion won ($323 million) to build a bio raw material production facility in Daejeon, South Korea. According to the company on Thursday, it will establish the facility in Dungok District in Daejeon.
[Exclusive] Celltrion Holdings takes first steps for U.S. listing
Celltrion Holdings is planning to list on Nasdaq as early as the end of 2024, a move that will allow the South Korean company to accurately evaluate its value in the global capital market and continue to grow as a healthcare investment company.
Global pharmaceutical companies vow to boost investments
Global pharmaceutical companies, including South Korean players, are expected to seek new growth engines that will be responsible for their businesses for the next 10 years based on accumulated capital.
Korean bio companies introduce novel drugs at industry event
South Korean pharmaceutical and biotech companies introduced new drugs they are strategically investing in at the 2024 J.P. Morgan Healthcare Conference, the world's largest bio healthcare event, taking place in San Francisco, the United States. SK biopharmaceutical Co. announced its global growth strategy for an independently developed epilepsy drug to global pharmaceutical and biotech companies and investors at the conference's Asia-Pacific (APAC) track on Tuesday.
New obesity treatments to be unveiled at industry event
Global pharmaceutical and bio companies are expected to unveil new obesity treatments at the 2024 edition of the J.P. Morgan Healthcare Conference, the world's largest bio healthcare event, scheduled to take place this week. J.P. Morgan's official website highlighted obesity treatments on its main page Saturday local time, with an explanation that there is increasing interest from investors in obesity drugs.
Chong Kun Dang signs biggest-ever technology transfer deal with Novartis
South Korea's Chong Kun Dang Pharmaceutical Corp. said on Monday that it has signed a 1.7 trillion won ($1.3 billion) technology transfer agreement with Novartis AG for a drug candidate to treat Charcot Marie Tooth disease. According to Chong Kun Dang, CKD-510 is a substance that selectively inhibits histone deacetylase 6 (HDAC6), a low-molecular-weight compound treating Charcot Marie Tooth disease, a type of hereditary peripheral neuropathy.
More Korean firms join U.S. Cancer Moonshot project
A total of twelve South Korean pharmaceutical and biotechnology companies are participating in the U.S. Cancer Moonshot initiative. According to industry sources on Sunday, companies including GC Cell Corp., HLB Co., Lunit Inc., Prestige Biopharma Ltd., LabGenomics Co., NgeneBio Co. Ltd., BL Science Corp., Gencurix Inc., Cubebio, EONE Diagnomics Genome Center Co., and Cytogen Inc. have joined the ambitious program to date.
PeproMene Bio unveils positive phase 1 data
PeproMene Bio is speeding up the development of a next-generation medication targeting different antigens to counter the high relapse rates associated with traditional chimeric antigen receptor T-cell therapies. PeproMene Bio held a conference in Seoul on Thursday to unveil the results of a phase 1 clinical trial for its investigative B cell activating factor receptor (BAFF-R) CAR-T therapy.
Macrogen ventures into microbiome DTC business
Macrogen Inc., a leading genomics analysis company in South Korea, is gearing up to launch its pioneering Direct-To-Consumer (DTC) business focused on the human microbiome and utilizing fecal samples. The new service will enable consumers to conveniently conduct gut microbiome tests from the comfort of their homes, eliminating the need for hospital visits.
Medical school popularity drives 28-year high in adult exam applicants
South Korea is set to witness a 28-year high in the percentage of high school graduate applicants in this year’s university entrance exam, accounting for 35.3 percent. Analysts note that the latest trend in the university exam is primarily attributed to the Ministry of Education’s decision to eliminate particularly challenging questions from the exam, combined with the growing demand for graduates seeking admission to medical schools across the nation.
Korean bio major Celltrion to merge with affiliate Celltrion Healthcare - Pulse by Maeil Business News Korea
South Korean biopharmaceutical company Celltrion Inc. announced Thursday that it will merge with Celltrion Healthcare Co., its sales and distribution affiliate, this year, in a move to grow into a bio giant with annual sales of over 4 trillion won ($2.99 billion). “Celltrion and Celltrion Healthcare have decided to complete the merger by December 28 in a board meeting,” said Celltrion Group Chairman and Founder Seo Jung-jin.
DNA testing services gain popularity among young population in Korea
Genetic testing is spreading like a trend among the young generation in Korea, reminiscent of the recent personality test craze. According to industry sources on Tuesday, there has been a sharp increase in demand for genetic testing services from young people. Particularly, the direct-to-consumer (DTC) market, which allows easy genetic testing from home without the need to visit specialized institutions, has become more popular, driving its activation.
Samsung Biologics has record first-half order backlog under CEO John Rim - Pulse by Maeil Business News Korea
South Korea’s Samsung Biologics Co., led by Chief Executive Officer John Rim, saw its cumulative order amount reach a record of 2.34 trillion won in the first six months this year. Analysts say that John Rim’s active global field management as CEO and head of the Global Sales Center have led to a surge of orders. According to industry sources on Monday, John Rim spent about 30 days in the first half of this year discussing partnerships with global pharmaceutical companies in the U.S. and Europe.
Samsung Biologics to begin early operations of No. 5 plant in 2025 - Pulse by Maeil Business News Korea
Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, will launch operations of its No. 5 factory five months ahead of schedule to meet surging customer demand.
S. Korea mulls measures to address shortage of emergency beds - Pulse by Maeil Business News Korea
To address the shortage of emergency beds, new measures are being explored in South Korea, which prioritizes the allocation of beds to severe patients by transferring mild cases to other facilities.
Government delays unveiling new telemedicine guidelines - Pulse by Maeil Business News Korea
The Korean government has delayed its plan to introduce new virtual healthcare guidelines which telemedicine would have only been allowed for medical consultations starting from a second visit to a doctor, causing confusion among patients and healthcare professionals. The Ministry of Health and Welfare announced on Wednesday that the government will introduce guidelines on the new virtual healthcare in September, after a transitional period over the next three months.
Government delays unveiling new telemedicine guidelines
The Korean government has delayed its plan to introduce new virtual healthcare guidelines which telemedicine would have only been allowed for medical consultations starting from a second visit to a doctor, causing confusion among patients and healthcare professionals. The Ministry of Health and Welfare announced on Wednesday that the government will introduce guidelines on the new virtual healthcare in September, after a transitional period over the next three months.
Songdo to take lead in forming global bio ecosystem: IFEZ Authority Commissioner - Pulse by Maeil Business News Korea
Songdo in Incheon, Korea, which boasts the world’s single largest annual production capacity of biomedicines, will play the role of boosting global cooperation in all stages in the bio industry from drug candidate exploration to clinical tests, said Kim Jin-yong, the commissioner of the Incheon Free Economic Zone (IFEZ) Authority.
Hanmi Pharmaceutical makes leadership reshuffle with no family succession
Hanmi Pharmaceutical Co. has made changes to its leadership structure with no signal of generational succession in the family business. Park Jae-hyun, head of manufacturing, was appointed as the new chief executive officer of the Korean pharmaceutical company, while CEO Woo Jong-soo, President Kwon Se-chang and Vice Chairman Lee Kwan-soon stepped down to serve as advisors.
Korea to remove mask mandate on public transportation from Monday - Pulse by Maeil Business News Korea
South Korea will lift the mask mandate for public transportation from Monday, ending the requirement after two years and five months, as Covid-19 is on the wane. “Prevention conditions are stable and no new mutations have been discovered since we eased the indoor mask mandate on Jan. 30,” said Han Chang-seob, vice minister of the Ministry of Public Administration and Security, on Wednesday.
IBD patients no longer tied to hospital thanks to new formulation meds
New medicines that can be self-injected at home drew attention at this year’s European Crohn’s and Colitis Organization (ECCO) conference held in Copenhagen, Denmark last week. Patient convenience in administration is especially prioritized for inflammatory bowel disease (IBD), which causes unknown diarrhea, abdominal pain, vomiting and bloody stools. This digestive disease mainly affects people in their 20s to 40s.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Shim
Contact Shim, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack